• 0 Citations
  • 0 h-Index
20102019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sangeetha Reddy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Melanoma Medicine & Life Sciences
Antineoplastic Combined Chemotherapy Protocols Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Neoplasm Drug Resistance Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Programmed Cell Death 1 Receptor Medicine & Life Sciences
Proto-Oncogene Proteins B-raf Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2010 2019

Erratum: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (Cell (2018) 175(4) (998–1013.e20), (S0092867418313941) (10.1016/j.cell.2018.10.038))

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., Freeman, S. S., Reuben, A., Hoover, P. J., Villani, A. C., Ivanova, E., Portell, A., Lizotte, P. H., Aref, A. R., Eliane, J. P., Hammond, M. R. & 15 others, Vitzthum, H., Blackmon, S. M., Li, B., Gopalakrishnan, V., Reddy, S. M., Cooper, Z. A., Paweletz, C. P., Barbie, D. A., Stemmer-Rachamimov, A., Flaherty, K. T., Wargo, J. A., Boland, G. M., Sullivan, R. J., Getz, G. & Hacohen, N., Jan 10 2019, In : Cell. 176, 1-2, 1 p.

Research output: Contribution to journalComment/debate

Open Access
T-cells
Immunotherapy
Melanoma
T-Lymphocytes

Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer

Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., Tsujikawa, T., Coussens, L. M., Wani, K., He, Y., Villareal, L., Wood, A., Rao, A., Woodward, W. A., Ueno, N. T., Krishnamurthy, S. & 2 others, Wargo, J. A. & Mittendorf, E. A., Jun 2019, In : Cancer Immunology Research. 7, 6, p. 1025-1035 11 p.

Research output: Contribution to journalArticle

Inflammatory Breast Neoplasms
Mast Cells
Drug Therapy
Tumor Microenvironment
Neoplasms

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., Freeman, S. S., Reuben, A., Hoover, P. J., Villani, A. C., Ivanova, E., Portell, A., Lizotte, P. H., Aref, A. R., Eliane, J. P., Hammond, M. R. & 15 others, Vitzthum, H., Blackmon, S. M., Li, B., Gopalakrishnan, V., Reddy, S. M., Cooper, Z. A., Paweletz, C. P., Barbie, D. A., Stemmer-Rachamimov, A., Flaherty, K. T., Wargo, J. A., Boland, G. M., Sullivan, R. J., Getz, G. & Hacohen, N., Nov 1 2018, In : Cell. 175, 4, p. 998-1013.e20

Research output: Contribution to journalArticle

Open Access
T-cells
Immunotherapy
Tumors
Melanoma
T-Lymphocytes

Erratum: Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (Nature medicine (2018) 24 11 (1649-1654))

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W. J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S. & 25 others, Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T. & Wargo, J. A., Dec 1 2018, In : Nature medicine. 24, 12, 1 p.

Research output: Contribution to journalComment/debate

Medicine
Melanoma
HTML
Names
Response Evaluation Criteria in Solid Tumors

Erratum to: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (Nature Medicine, (2018), 24, 11, (1649-1654), 10.1038/s41591-018-0197-1)

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W. J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S. & 25 others, Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T. & Wargo, J. A., Dec 1 2018, In : Nature Medicine. 24, 12, 1 p.

Research output: Contribution to journalComment/debate

Medicine
Melanoma
HTML
Names
Response Evaluation Criteria in Solid Tumors